Despite the great success of immune-checkpoint inhibitor (ICI) treatment for multiple cancers. evidence for the clinical use of ICIs in acute myeloid leukemia (AML) remains inadequate. Further exploration of the causes of immune evasion in the bone marrow (BM) environment. the primary leukemia site. https://herbsdailyes.shop/product-category/childrens-cold/
PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow
Internet 22 hours ago jdewlgykp6d8Web Directory Categories
Web Directory Search
New Site Listings